<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>354</serviceExecutionTime><Drug id="57669"><DrugName>terbinafine-based local onychomycosis therapy, Arpida</DrugName><DrugNamesKey><Name id="42756630">terbinafine</Name></DrugNamesKey><DrugSynonyms><Name><Value>terbinafine</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>terbinafine-based local onychomycosis therapy, Arpida</Value></Name><Name><Value>terbinafine-based local onychomycosis therapy, TLT</Value></Name><Name><Value>91161-71-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesSecondary><Company id="1019742">TLT Medical Ltd</Company><Company id="25843">Evolva Holding SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1019742" type="Company"><TargetEntity id="4297781821" type="organizationId">Tlt Medical Ltd in Liquidation</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="25843" type="Company"><TargetEntity id="4295890719" type="organizationId">Evolva Holding SA</TargetEntity></SourceEntity><SourceEntity id="1775" type="ciIndication"><TargetEntity id="10030338" type="MEDDRA"></TargetEntity><TargetEntity id="D014009" type="MeSH"></TargetEntity><TargetEntity id="-2019669150" type="omicsDisease"></TargetEntity><TargetEntity id="827" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1748" type="Action"><TargetEntity id="1508" type="Mechanism">Homoserine Dehydrogenase (Fungal) Inhibitors</TargetEntity><TargetEntity id="1059" type="Mechanism">Efflux Pump (Fungal) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="351" type="Action"><TargetEntity id="492" type="Mechanism">Squalene Monooxygenase Inhibitors</TargetEntity><TargetEntity id="3836" type="Mechanism">Squalene Monooxygenase (Fungal) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1775">Onychomycosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="351">Squalene epoxidase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15177">Topical dermatological antifungal product</Action><Action id="161">Ergosterol synthesis inhibitor</Action><Action id="1748">Fungicide</Action></ActionsSecondary><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="764">Local formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>J2</Code><Name>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</Name></Ephmra><Ephmra><Code>D1A1</Code><Name>Topical dermatological antifungals</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-28T06:18:01.000Z</LastModificationDate><ChangeDateLast>2019-01-28T00:00:00.000Z</ChangeDateLast><AddedDate>2007-07-19T13:17:16.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25843" linkType="Company"&gt;Arpida&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="1019742" linkType="Company"&gt;TLT Medical&lt;/ulink&gt;, was developing a therapy comprising laser pre-treatment followed by topical application of a locally acting  formulation of &lt;ulink linkID="4533" linkType="Drug"&gt;terbinafine&lt;/ulink&gt;, for the potential treatment of onychomycosis. By July 2007, European approval had been granted for a phase III trial, which was scheduled to begin 'in the short term'.  At that time, the company planned to file for approval in late 2008 or early 2009 [&lt;ulink linkID="814257" linkType="Reference"&gt;814257&lt;/ulink&gt;],  [&lt;ulink linkID="825653" linkType="Reference"&gt;825653&lt;/ulink&gt;]; in January 2008, the phase III trial began  [&lt;ulink linkID="869274" linkType="Reference"&gt;869274&lt;/ulink&gt;]. However, in December 2008, Arpida stopped enrollment in the phase III onychomycosis trial in order to cuts costs to focus on the approval of &lt;ulink linkID="34984" linkType="Drug"&gt;iclaprim&lt;/ulink&gt;. At that time, the drug program would be reviewed [&lt;ulink linkID="971188" linkType="Reference"&gt;971188&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt; By July 2007, European approval had been granted for a phase III trial, which was scheduled to begin "in the short term" [&lt;ulink linkID="814257" linkType="Reference"&gt;814257&lt;/ulink&gt;],  [&lt;ulink linkID="825653" linkType="Reference"&gt;825653&lt;/ulink&gt;]. In January 2008, Arpida started patient screening for a pivotal phase III trial of the therapy. The trial was to be completed by early 2009. The European, open-label, 48-week trial would assess efficacy, safety and tolerability of the laser pre-treatment plus daily topical terbinafine therapy versus daily ciclopirox lacquer application in 220 patients with mild-to-moderate toenail onychomycosis. The primary objective was 100% clear nails and negative fungal culture and KOH microscopy. The secondary objectives included time-to-complete, safety and tolerability [&lt;ulink linkID="869274" linkType="Reference"&gt;869274&lt;/ulink&gt;]. In December 2008, Arpida stopped enrollment in the phase III onychomycosis trial  in order to cuts costs to focus on the approval of iclaprim [&lt;ulink linkID="971188" linkType="Reference"&gt;971188&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2006, TLT filed &lt;ulink linkID="PA3521088" linkType="Patent"&gt;WO-2007076619&lt;/ulink&gt; claiming use of a composition containing an active agent (especially terbinafine) and then covering the nail with a protective layer  for the treatment of nail and non-nail diseases.&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25843">Evolva Holding SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1775">Onychomycosis</Indication><StatusDate>2008-12-16T00:00:00.000Z</StatusDate><Source id="971188" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25843">Evolva Holding SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1775">Onychomycosis</Indication><StatusDate>2008-12-16T00:00:00.000Z</StatusDate><Source id="971188" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1019742">TLT Medical Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1775">Onychomycosis</Indication><StatusDate>2007-07-18T00:00:00.000Z</StatusDate><Source id="814257" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25843">Evolva Holding SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1775">Onychomycosis</Indication><StatusDate>2008-01-22T00:00:00.000Z</StatusDate><Source id="869274" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25843">Evolva Holding SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1775">Onychomycosis</Indication><StatusDate>2007-07-18T00:00:00.000Z</StatusDate><Source id="814257" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01759"><Name>Squalene epoxidase</Name><SwissprotNumbers><Swissprot>O13306</Swissprot><Swissprot>O48651</Swissprot><Swissprot>P32476</Swissprot><Swissprot>P52019</Swissprot><Swissprot>P52020</Swissprot><Swissprot>Q14534</Swissprot><Swissprot>Q75F69</Swissprot><Swissprot>Q92206</Swissprot><Swissprot>Q9C1W3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(C)(C)C#C/C=C/CN(C)Cc1cccc2c1cccc2</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>